A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC
CA242-0001
Phase 1 other active
Quick answer
A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC for Advanced Clear Cell Renal Cell Carcinoma is a Phase 1 program (other) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advanced Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active